IP6: From Seeds to Science—A Natural Compound’s Path to Clinical Promise

Inositol hexaphosphate (IP6), also known as phytic acid, has historically been classified as an antinutrient due to its mineral-chelating properties, which were believed to impair nutrient absorption. Early reports fueled concerns that high dietary phytate intake could contribute to mineral deficiencies, albeit without direct scientific evidence, particularly in populations lacking dietary diversity. However, lifetime animal experiments have demonstrated that IP6 does not have any negative effect on mineral bioavailability and if there is any in humans, it is largely context-dependent. Even more importantly, beyond nutritional implications, IP6 has emerged as a bioactive molecule with promising therapeutic potential across various cancer types and clinical conditions. Preclinical and clinical research indicate that IP6, alone or in tandem with inositol (Ins), selectively targets cancer cells and enhances chemotherapy efficacy. Growing evidence also suggests that IP6 plays a protective role in cardiovascular health, neurodegenerative disorders, and metabolic diseases. While clinical trials remain limited, extensive in vitro, in vivo, and epidemiological studies support a shift in how IP6 is perceived among the scientific community—moving from an antinutrient to a health-promoting compound. As research progresses, further clinical investigations are essential to fully elucidate IP6’s therapeutic applications and its benefit to disease prevention.